Characterization of Eltenac and novel COX-2 selective thiopheneacetic acid analogues in vitro and in vivo

Biochemical Pharmacology

Volumn 76, Issue 6, 2008, Pages 717-725

  Klein, Thomas ^a   Dullweber, Frank ^a   Brehm, Christoph ^a   Prinz, Walter ^a   Baudler, Monika ^a   Figala, Volker ^a   Herrmann, Michael ^a  

^a Nycomed GmbH   (Germany)

Author keywords

COXib; Cyclooxygenase; Eltenac; NSAID; Prostacyclin

Indexed keywords

ACETYLSALICYLIC ACID; BYK 123; BYK 124; BYK 127; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; ELTENAC; LUMIRACOXIB; NITRATE; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTACYCLIN; PROSTAGLANDIN E2; THIOPHENE ACETIC ACID DERIVATIVE; THIOPHENE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CARTILAGE CELL; CONTROLLED STUDY; DRUG BINDING; DRUG HALF LIFE; DRUG MEGADOSE; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; FEEDING; FEMALE; GASTROINTESTINAL TOXICITY; GASTROINTESTINAL TRACT; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; LOW DRUG DOSE; MALE; MICROSOME; MOLECULAR MODEL; NONHUMAN; PAW EDEMA; PRIORITY JOURNAL; SINGLE DRUG DOSE; SPRAGUE DAWLEY RAT; SURVIVAL; ULCEROGENESIS;

ACETIC ACID; ANILINE COMPOUNDS; ANIMALS; CELLS, CULTURED; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; EDEMA; FEMALE; HUMANS; MALE; RATS; RATS, SPRAGUE-DAWLEY; STOMACH ULCER; THIOPHENES;

EID: 50649095679     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2008.06.025     Document Type: Article

References (30)

1. Klein T., Nusing R.M., Pfeilschifter J., and Ullrich V. Selective inhibition of cyclooxygenase 2. Biochem Pharmacol 48 (1994) 1605-1610
2. Futaki N., Takahashi S., Yokoyama M., Arai I., Higuchi S., and Otomo S. NS-398, a new anti-inflammatory agent, selectively inhibits prostaglandin G/H synthase/cyclooxygenase (COX-2) activity in vitro. Prostaglandins 47 (1994) 55-59
3. Masferrer J.L., Zweifel B.S., Manning P.T., Hauser S.D., Leahy K.M., Smith W.G., et al. Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic. Proc Natl Acad Sci USA 91 (1994) 3228-3232
4. Bresalier R.S., Sandler R.S., Quan H., Bolognese J.A., Oxenius B., Horgan K., et al. Cardiovascular events associated with Rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 352 (2005) 1092-1102
5. Solomon S.D., McMurray J.J., Pfeffer M.A., Wittes J., Fowler R., Finn P., et al. Cardiovascular risk associated with Celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 352 (2005) 1071-1080
6. Cullen L., Kelly L., Connor S.O., and Fitzgerald D.J. Selective cyclooxygenase-2 inhibition by nimesulide in man. J Pharmacol Exp Ther 287 (1998) 578-582
7. Farkouh M.E., Kirshner H., Harrington R.A., Ruland S., Verheugt F.W., Schnitzer T.J., et al. Comparison of Lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial. The Lancet 364 (2004) 675-684
8. Schnitzer T.J., Burmester G.R., Mysler E., Hochberg M.C., Doherty M., Ehrsam E., et al. Comparison of Lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. The Lancet 364 (2004) 665-674
9. Brune K., and Hinz B. Selective cyclooxygenase-2 inhibitors: similarities and differences. Scand J Rheumatol 33 (2004) 1-6
10. Topol E.J., and Falk G.W. A coxib a day won't keep the doctor away. The Lancet 364 (2004) 639-640
11. Sandelin J., Harilainen A., Crone H., Hamberg P., Forsskahl B., and Tamelander G. Local NSAID gel (Eltenac) in the treatment of osteoarthritis of the knee. A double blind study comparing Eltenac with oral Diclofenac and placebo gel. Scand J Rheumatol 26 (1997) 287-292
12. Cashin C.H., Dawson W., and Kitchen E.A. The pharmacology of benoxaprofen (2-[4-chlorophenyl]-alpha-methyl-5-benzoxazole acetic acid), LRCL 3794, a new compound with antiinflammatory activity apparently unrelated to inhibition of prostaglandin synthesis. J Pharm Pharmacol 29 (1977) 330-336
13. Mais A., Klein T., Ullrich V., Schudt C., and Lauer G. Prostanoid pattern and iNOS expression during chondrogenic differentiation of human mesenchymal stem cells. J Cell Biochem 98 (2006) 798-809
14. Berman H.M., Westbrook J., Feng Z., Gilliland G., Bhat T.N., Weissig H., et al. The Protein Data Bank. Nucleic Acids Res 28 (2000) 235-242
15. Rowlinson S.W., Kiefer J.R., Prusakiewicz J.J., Pawlitz J.L., Kozak K.R., Kalgutkar A.S., et al. A novel mechanism of cyclooxygenase-2 inhibition involving interactions with Ser-530 and Tyr-385. J Biol Chem 278 (2003) 45763-45769
16. Kurumbail R.G., Stevens A.M., Gierse J.K., McDonald J.J., Stegeman R.A., Pak J.Y., et al. Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. Nature 19-26 384 (1996) 644-648
17. Chauret N., Guay D., Li C., Day S., Silva J., Blouin M., et al. Improving metabolic stability of phosphodiesterase-4 inhibitors containing a substituted catechol: prevention of reactive intermediate formation and covalent binding. Bioorg Med Chem Lett 12 (2002) 2149-2152
18. Wallace J.L., Cirino G., McKnight G.W., and Elliott S.N. Reduction of gastrointestinal injury in acute endotoxic shock by flurbiprofen nitroxybutylester. Eur J Pharmacol 280 (1995) 63-68
19. Silverstein F.E., Faich G., Goldstein J.L., Simon L.S., Pincus T., Whelton A., et al. Gastrointestinal toxicity with Celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. J Am Med Assoc 284 (2000) 1247-1255
20. Walker M.C., Kurumbail R.G., Kiefer J.R., Moreland K.T., Koboldt C.M., Isakson P.C., et al. A three-step kinetic mechanism for selective inhibition of cyclo-oxygenase-2 by diarylheterocyclic inhibitors. Biochem J 357 (2001) 709-718
21. Klein T., and Nusing R.M. Mechanism of cyclooxygenase-2 inhibition by indanone derivatives. Adv Exp Med Biol 407 (1997) 503-507
22. Selinsky B.S., Gupta K., Sharkey C.T., and Loll P.J. Structural analysis of NSAID binding by prostaglandin H2 synthase: time-dependent and time-independent inhibitors elicit identical enzyme conformations. Biochemistry 40 (2001) 5172-5180
23. Chan C.C., Boyce S., Brideau C., Charleson S., Cromlish W., Ethier D., et al. Rofecoxib [Vioxx, MK-0966; 4-(4′-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles. J Pharmacol Exp Ther 290 (1999) 551-560
24. Esser R., Berry C., Du Z., Dawson J., Fox A., Fujimoto R.A., et al. Preclinical pharmacology of Lumiracoxib: a novel selective inhibitor of cyclooxygenase-2. Br J Pharmacol 144 (2005) 538-550
25. Burgaud J.L., Riffaud J.P., and Del Soldato P. Nitric-oxide releasing molecules: a new class of drugs with several major indications. Curr Pharm Des 8 (2002) 201-213
26. Keeble J.E., and Moore P.K. Pharmacology and potential therapeutic applications of nitric oxide-releasing non-steroidal anti-inflammatory and related nitric oxide-donating drugs. Br J Pharmacol 137 (2002) 295-310
27. Davies N.M., Roseth A.G., Appleyard C.B., McKnight W., Del Soldato P., Calignano A., et al. NO-naproxen vs. naproxen: ulcerogenic, analgesic and anti-inflammatory effects. Aliment Pharmacol Ther 11 (1997) 69-79
28. Wallace J.L., Reuter B., Cicala C., McKnight W., Grisham M., and Cirino G. A Diclofenac derivative without ulcerogenic properties. Eur J Pharmacol 257 (1994) 249-255
29. Fiorucci S., Antonelli E., Burgaud J.L., and Morelli A. Nitric oxide-releasing NSAIDs: a review of their current status. Drug Saf 24 (2001) 801-811
30. Blobaum A.L., and Marnett L.J. Molecular determinants for the selective inhibition of cyclooxygenase-2 by Lumiracoxib. J Biol Chem 282 (2007) 16379-16390